A Brief Digital Screening and Intervention Tool for Parental and Adolescent Tobacco and Electronic Cigarette Use in Pediatric Medical Care in Canada: Protocol for a Pilot Randomized Controlled Trial
Chadi N., Diamant E., Perez T., Al-Saleh A., Sylvestre M.-P., O’Loughlin J., Winickoff J.P., Drouin O., JMIR Research Protocols, 2023
Evaluation of audit and feedback to family physicians on prescribing of opioid analgesics to opioid-naïve patients: A pragmatic randomized delay trial
McCracken RK, Narayan S, Maclure M, Cooper I, Cui Z, Cullen W, Dormuth C, Hamilton MA, Nolan S, Singer J, Socías ME, Wong S, Klimas J., Contemp Clin Trials. 2023
“I thought it was for guys that did needles”: Medication perceptions and lay expertise among medical research participants
Jaffe K, Richardson L., Subst Use Addict Treat. 2023
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
Bakouni H, McAnulty C, Tatar O, Socias ME, Le Foll B, Lim R, Ahamad K, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Am J Addict. 2023
Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada
Whitehurst DGT, Mah C, Krebs E, Enns B, Socias ME, Jutras-Aswad D, Le Foll B, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Qual Life Res. 2023
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
Bastien G, McAnulty C, Ledjiar O, Socias ME, Le Foll B, Lim R, Hassan AN, Brissette S, Marsan S, Talbot A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Can J Psychiatry. 2023
Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial
Mocanu V, Bozinoff N, Wood E, Jutras-Aswad D, Le Foll B, Lim R, Cheol Choi J, Yin Mok W, Eugenia Socias M; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse.,
Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder
Enns B, Krebs E, Whitehurst DGT, Jutras-Aswad D, Le Foll B, Socias ME, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., Drug Alcohol Depend. 2023
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study
Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse., J Subst Use Addict Treat. 2023
Rating versus ranking in a Delphi survey: a randomized controlled trial
Del Grande C., Kaczorowski J., Trials, 2023
